Home Behandelprotocollen GvHD Richtlijnen en literatuur


Er is op dit moment geen behandelrichtlijn voor GvHD.


  1. Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11(12):945-956
  2. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550-1561
  3. Socie G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside. Blood. 2009;114(20):4327-4336
  4. Zeiser R, Socie G, Blazar BR. Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation. Br J Haematol. 2016
  5. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18(4):295-304
  6. Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: A report from the mount sinai acute GVHD international consortium. Biol Blood Marrow Transplant. 2016;22(1):4-10
  7. Leisenring WM, Martin PJ, Petersdorf EW, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood. 2006;108(2):749-755
  8. Mohty M, et al. Refractory acute graf-versus-host disease: a new working definition beyond corticosteroid refractoriness. Blood 2020; 136(17): 1903-1906. e-pub ahead of print 2020/08/07; doi: 10.1182/blood.2020007336


Ga terug naar de homepage Graft versus host disease.

Ga terug naar de algemene homepage Behandelprotocollen